MA49771A - Induction d'une immunité protectrice contre des antigènes - Google Patents
Induction d'une immunité protectrice contre des antigènesInfo
- Publication number
- MA49771A MA49771A MA049771A MA49771A MA49771A MA 49771 A MA49771 A MA 49771A MA 049771 A MA049771 A MA 049771A MA 49771 A MA49771 A MA 49771A MA 49771 A MA49771 A MA 49771A
- Authority
- MA
- Morocco
- Prior art keywords
- induction
- immunity against
- protective immunity
- against antigens
- antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541293P | 2017-08-04 | 2017-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49771A true MA49771A (fr) | 2020-06-10 |
Family
ID=65233106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049771A MA49771A (fr) | 2017-08-04 | 2018-08-03 | Induction d'une immunité protectrice contre des antigènes |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11596677B2 (fr) |
| EP (1) | EP3661547A4 (fr) |
| CN (1) | CN111182920B (fr) |
| BR (1) | BR112020002374A2 (fr) |
| MA (1) | MA49771A (fr) |
| WO (1) | WO2019028396A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050724A1 (fr) | 2017-01-23 | 2018-07-26 | University Of Florida Research Foundation, Incorporated | Induction d'immunite protectrice contre des antigenes |
| AU2021410776A1 (en) * | 2020-12-23 | 2023-05-04 | Chan Zuckerberg Biohub, Inc. | Bacteria-engineered to elicit antigen-specific t cells |
| WO2022231043A1 (fr) * | 2021-04-30 | 2022-11-03 | 전남대학교산학협력단 | Souche atténuée de salmonella gallinarum et son utilisation |
| CN116287084A (zh) * | 2022-11-28 | 2023-06-23 | 广东筑美生物医疗科技有限公司 | 一种酶转化合成脱氧胆酸的方法 |
| CN117737001B (zh) * | 2022-12-27 | 2024-08-09 | 菲吉乐科(南京)生物科技有限公司 | 一种防治犬细菌性腹泻的大肠杆菌噬菌体及其应用 |
| CN121248709A (zh) * | 2023-11-01 | 2026-01-02 | 东南大学 | 一种靶向cldn4蛋白的多肽及其制备方法和应用 |
| CN119192395B (zh) * | 2024-09-20 | 2025-03-14 | 中国动物卫生与流行病学中心 | 一种抗禽产气荚膜梭菌的亚单位疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY149604A (en) | 2005-04-18 | 2013-09-13 | Schering Plough Ltd | C.perfringens alpha toxoid vaccine |
| EP2162150A4 (fr) * | 2007-06-22 | 2011-10-12 | Univ Guelph | Vaccin contre le clostridium perfringens |
| US8465755B2 (en) * | 2007-10-05 | 2013-06-18 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against enteric pathogens |
| WO2010045620A1 (fr) * | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Bactérie recombinante pouvant éliciter une réponse immunitaire contre le streptococcus pneumoniae |
| WO2011150421A2 (fr) | 2010-05-28 | 2011-12-01 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Bactérie recombinante permettant de diminuer la croissance tumorale |
| WO2012087483A1 (fr) | 2010-11-24 | 2012-06-28 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Bactérie recombinante renfermant un système toxine-antitoxine |
| CA2867516A1 (fr) | 2012-04-02 | 2013-10-10 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Bacterie recombinante pour induire une reponse immunitaire cellulaire |
| EP2925346A1 (fr) | 2012-11-30 | 2015-10-07 | Universite d'Auvergne Clermont I | Utilisation de microorganismes pour diminuer le taux de triméthylamine dans une cavité du corps humain, notamment pour le traitement de la triméthylaminurie ou d'une vaginose bactérienne et la prévention des maladies cardiovasculaires |
| WO2015118541A1 (fr) | 2014-02-05 | 2015-08-13 | Gavish-Galilee Bio Applications Ltd | Système génétique pour générer des bactéries inactivées ou atténuées de manière conditionnelle |
| WO2018018041A1 (fr) | 2016-07-22 | 2018-01-25 | University Of Florida Research Foundation, Incorporated | Conception d'un vaccin anti-zikv qui n'a pas de réaction croisées avec la dengue. |
| CA3050724A1 (fr) | 2017-01-23 | 2018-07-26 | University Of Florida Research Foundation, Incorporated | Induction d'immunite protectrice contre des antigenes |
-
2018
- 2018-08-03 CN CN201880065105.1A patent/CN111182920B/zh active Active
- 2018-08-03 BR BR112020002374-4A patent/BR112020002374A2/pt unknown
- 2018-08-03 MA MA049771A patent/MA49771A/fr unknown
- 2018-08-03 WO PCT/US2018/045231 patent/WO2019028396A1/fr not_active Ceased
- 2018-08-03 US US16/636,251 patent/US11596677B2/en active Active
- 2018-08-03 EP EP18841409.8A patent/EP3661547A4/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020002374A2 (pt) | 2020-09-08 |
| WO2019028396A8 (fr) | 2020-02-13 |
| US11596677B2 (en) | 2023-03-07 |
| EP3661547A4 (fr) | 2021-06-09 |
| WO2019028396A1 (fr) | 2019-02-07 |
| CN111182920B (zh) | 2023-09-12 |
| US20200368339A1 (en) | 2020-11-26 |
| CN111182920A (zh) | 2020-05-19 |
| EP3661547A1 (fr) | 2020-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49771A (fr) | Induction d'une immunité protectrice contre des antigènes | |
| MA47317A (fr) | Induction d'immunité protectrice contre des antigènes | |
| EP3507298A4 (fr) | Détection d'un carcinome hépatocellulaire | |
| EP3362472A4 (fr) | Compositions et méthodes d'inhibition d'antigènes spécifiques à une lignée | |
| EP3303083A4 (fr) | Réduction des risques d'itinéraire | |
| EP3526328A4 (fr) | Polythérapie pour l'inhibition de c3 | |
| EP3360043A4 (fr) | Évaluation de l'efficacité de technologies de cybersécurité | |
| EP3341861A4 (fr) | Recommandation de vidéos d'après des titres de vidéos | |
| MA49715A (fr) | Oligomères et conjugués d'oligomères | |
| EP3419674A4 (fr) | Immunothérapie de ciblage de l'amyloïdose | |
| EP3415146A4 (fr) | Inhibiteur de l'activation des inflammasomes | |
| MA43378A (fr) | Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques | |
| DK3410822T3 (da) | Elektromagnetisk induktionsopvarmer | |
| EP3478315A4 (fr) | Méthodes et compositions d'inhibition du récepteur immunitaire inhibiteur | |
| EP3347334A4 (fr) | Déshydrohalogénation d'hydrochlorofluorocarbones | |
| EP3533253A4 (fr) | Régulation d'encombrement 5g | |
| BE1022355A1 (fr) | Nouvelles méthodes d'induction d'une réponse immunitaire | |
| EP3403094A4 (fr) | Bilbiothèque des produits d'addition ligand d'arn de transfert | |
| ITUB20153017A1 (it) | Dispositivo per l'avvolgimento di prodotti | |
| EP3345618A4 (fr) | AGENT DESTINÉ À AMÉLIORER L'IMMUNITÉ CONTRE LE CANCER EMPLOYANT UN ANTAGONISTE D'Allergine-1 | |
| MA43764A (fr) | Inhibiteur monovalent de l'interaction hutnfr1 | |
| EP3335725A4 (fr) | Inducteur de la réponse immunitaire | |
| EP3781195A4 (fr) | Antigènes vaccinaux chimériques contre l'anaplasmose | |
| EP3697947A4 (fr) | Prise en compte d'effets d'ajustement induit | |
| DK3535461T3 (da) | Sprængningsbeskyttelsesvæg |